Targeted proteomics via NULISAseq identifies blood‐detectable markers of disease progression in familial frontotemporal lobar degeneration
Alterations in plasma protein abundance are measurable in familial FTLD prior to predicted symptom onset. The validity and brain-based relevance of blood-detectable NULISA targets is bolstered by the observed convergence with plasma Simoa and CSF SomaScan. Replication of top hits in larger familial and sporadic FTLD sample sizes is warranted to determine generalizability and suitability for clinical trials.
Authors
- Hilary W. Heuer (ORCID: https://orcid.org/0000-0002-3776-1685)
- Joshua D. Downer (ORCID: https://orcid.org/0000-0003-3817-6733)
- Adam M. Staffaroni (ORCID: https://orcid.org/0000-0002-3903-9805)
- Peter Alexander Ljubenkov (ORCID: https://orcid.org/0000-0002-3348-9215)
- Leah K. Forsberg (ORCID: https://orcid.org/0000-0003-4086-9598)
- Argentina Lario Lago
- Julia D Webb
- Brad F Boeve
- Julio C. Rojas
- Lawren VandeVrede
- Adam L. Boxer
- Howard J. Rosen
- Leonard Petrucelli
- Rowan Saloner
- Tania F Gendron
Institutions
- University of California, San Francisco (US)
- WinnMed (US)
- University Memory and Aging Center (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_098644
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00